Renal clearance and protein binding of melphalan in patients with cancer.
作者： PhillipA. Reece , HeatherS. Hill , R.Malcolm Green , RaymondG. Morris , BarryM. Dale
DOI: 10.1007/BF00254244
关键词: Surgery 、 Renal function 、 Kidney 、 Urine 、 Creatinine 、 Chemotherapy 、 Urology 、 Serum albumin 、 Melphalan 、 Chemistry 、 Pharmacokinetics
摘要: The renal clearance of melphalan and the fraction unbound in plasma were determined after intravenous infusion 5 mg/m2 over min nine patients with cancer to obtain information regarding mechanism handling melphalan. Four underwent bone marrow transplantation also received an IV dose 220 mg/m2. Total ranged from 66.0 272 ml/min per m2; percentage excreted unchanged urine, 2.5% 92.8%; clearance, 4.1 188 plasma, 0.0598 0.460; t1/2β, 39.4 84.3 min. Unbound calculated for each patient 441 3356 m2 15 961 respectively not related serum albumin, creatinine or clearance. exctreted urine flow. There was evidence active secretion kidney possible reabsorption. no significant paired differences disposition between high- low-dose studies. Highly variable involving may contribute part large interpatient total cancer.
springer.com
sci-hub.se 参考文章(13)
Andrew G. Bosanquet, Edward D. Gilby, Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. European Journal of Cancer and Clinical Oncology. ,vol. 18, pp. 355- 362 ,(1982) , 10.1016/0277-5379(82)90006-2
Alain Gouyette, Olivier Hartmann, Jos�-Luis Pico, Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemotherapy and Pharmacology. ,vol. 16, pp. 184- 189 ,(1986) , 10.1007/BF00256174
Phillip A. Reece, Barry M. Dale, Raymond G. Morris, Dusan Kotasek, David Gee, Stephen Rogerson, Effect of L-leucine on oral melphalan kinetics in patients. Cancer Chemotherapy and Pharmacology. ,vol. 20, pp. 256- 258 ,(1987) , 10.1007/BF00570497
N. H. Greig, D. J. Sweeney, S. I. Rapoport, Melphalan concentration dependent plasma protein binding in healthy humans and rats. European Journal of Clinical Pharmacology. ,vol. 32, pp. 179- 185 ,(1987) , 10.1007/BF00542192
Larry Brox, Lucille Birkett, Andrew Belch, Pharmacology of intravenous melphalan in patients with multiple myeloma Cancer Treatment Reviews. ,vol. 6, pp. 27- 32 ,(1979) , 10.1016/S0305-7372(79)80007-9
J. Ninane, R. Baurain, A. de Selys, A. Trouet, G. Cornu, High dose melphalan in children with advanced malignant disease. A pharmacokinetic study. Cancer Chemotherapy and Pharmacology. ,vol. 15, pp. 263- 267 ,(1985) , 10.1007/BF00263898
K. W. Woodhouse, P. Hamilton, A. Lennard, M. D. Rawlins, The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous oral study using a conventional dose regimen European Journal of Clinical Pharmacology. ,vol. 24, pp. 283- 285 ,(1983) , 10.1007/BF00613833
David T. Vistica, Cellular pharmacokinetics of the phenylalanine mustards Pharmacology & Therapeutics. ,vol. 22, pp. 379- 405 ,(1983) , 10.1016/0163-7258(83)90009-8
I.A.-K. Taha, R.A. Ahmad, D.W. Rogers, J. Pritchard, H.J. Rogers, Pharmacokinetics of melphalan in children following high-dose intravenous injection Cancer Chemotherapy and Pharmacology. ,vol. 10, pp. 212- 216 ,(1983) , 10.1007/BF00255766
Claude Ardiet, Brigitte Tranchand, Pierre Biron, Paul Rebattu, Thierry Philip, Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Cancer Chemotherapy and Pharmacology. ,vol. 16, pp. 300- 305 ,(1986) , 10.1007/BF00293997